[REMOVED] Antonio Ceriello: A New Era in Diabetes Care

touchENDOCRINOLOGY caught up with Dr Antonio Ceriello to discuss the European Steering Committee’s ‘A New Era in Diabetes Care’ report and what this means for patients with type 2 diabetes, chronic kidney disease and cardiovascular disease. For further information, please click here for the full report. Questions 1. Please provide a brief overview of the […]

Christopher Cannon, ADA 2020: Results of the Phase III VERTIS-CV Trial

It was a pleasure to speak to Christopher Cannon to discuss the much-anticipated results of the VERTIS-CV trial (ClinicalTrials.gov Identifier: NCT01986881) evaluating the efficacy and safety and cardiovascular outcomes of ertugliflozin in type 2 diabetes. Questions 1. Could you tell us a little about the VERTIS-CV trial and its primary and secondary outcome data? (0:06) […]

Stefano Del Prato, EASD 2020 – Planning a virtual meeting

We were delighted to speak with EASD President Prof. Stefano Del Prato (University of Pisa and University Hospital of Pisa) ahead of this year’s virtual meeting to hear how the meeting has been adapted to a virtual format. Questions 1. How did you go about planning for virtual EASD?(00:05) 2. What key features are you […]

Stefano Del Prato, EASD 2020 – What to look out for at this year’s meeting

We caught up with EASD President Prof. Stefano Del Prato (University of Pisa and University Hospital of Pisa) ahead of this year’s virtual meeting to hear about the key topics being discussed. Disclosures: Prof. Del Prato has received research support from AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme and served on the advisory board for […]

Acromegaly Due to McCune–Albright Syndrome

US Endocrinology. 2020;16(1):47–50 DOI: https://doi.org/10.17925/USE.2020.16.1.47

McCune–Albright syndrome (MAS) is a genetic disorder first described by McCune1 and Albright2  in the 1930s as a triad of polyostotic fibrous dysplasia, café-au-lait spots, and precocious puberty (Figure 1). Since then, other hyperfunctioning endocrinopathies have been described in MAS, including hyperthyroidism, Cushing’s syndrome, hypophosphatemic osteomalacia, and acromegaly.3 Patients with MAS display mosaicism as the disease results […]

Pheochromocytoma Due to TMEM127 Mutation – The Importance of Genetic Testing for Clinical Decision

European Endocrinology. 2020;16(1):72-4

Catecholamine-secreting tumours that arise from chromaffin cells of the adrenal medulla and the sympathetic ganglia are respectively referred to as pheochromocytomas and paragangliomas. The term paraganglioma is also used for tumours derived from parasympathetic tissue in the head and neck, most of which do not produce catecholamines.1 The classic triad of symptoms in patients with […]

Diabetic Polyneuropathy – Advances in Diagnosis and Intervention Strategies

European Endocrinology. 2020;16(1):15–20

Diabetic polyneuropathy (DPN) is the most common microvascular complication of diabetes, affecting approximately 50% of all people with diabetes (type 1 diabetes [T1D] and type 2 diabetes [T2D]).1 DPN is a major cause of disability due to sensory loss, gait instability and fall‐related injuries,1–5 and is the strongest risk factor for diabetic foot ulceration and amputation.1–4 Up to […]

Cost Comparison of Flash Continuous Glucose Monitoring with Self-monitoring of Blood Glucose in Adults with Type 1 or Type 2 Diabetes Using Intensive Insulin—From a US Private Payer Perspective

US Endocrinology. 2020;16(1):24–30 DOI: https://doi.org/10.17925/USE.2020.16.1.24

Unmet needs for glucose monitoring in people with diabetes mellitus using intensive insulin Glucose monitoring is essential for people using intensive insulin to inform adjustments to the treatment and management of diabetes. Evidence suggests many people do not adhere to the recommended testing frequency with self-monitoring of blood glucose (SMBG). In the USA, it was […]